Manus Biosynthesis Financing
Manus Biosynthesis, Inc., Corporation just submitted form D announcing $3.00 million equity financing. This is a new filing. Manus Biosynthesis was able to fundraise $300,000 so far. That is 10.00% of the financing offer. The total offering amount was $3.00 million. The offering form was filed on 2016-10-06. The reason for the financing was: unspecified. The fundraising still has about $2.70 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Manus Biosynthesis is based in Massachusetts. The firm’s business is Biotechnology. The form D was filed by Ajikumar Parayil President. The company was incorporated more than five years ago. The filler’s address is: 1030 Masssachusetts Avenue, Suite 300, Cambridge, Ma, Massachusetts, 02138. Ajikumar Parayil is the related person in the form and it has address: C/O Manus Biosynthesis, Inc., 1030 Massachusetts Avenue, Suite 300, Cambridge, Ma, Massachusetts, 02138. Link to Manus Biosynthesis Filing: 000168623016000002.
Analysis of Manus Biosynthesis Offering
On average, companies in the Biotechnology sector, sell 73.77% of the total offering amount. Manus Biosynthesis sold 10.00% of the offering. The financing is still open. The average investment offering size for companies in the Biotechnology industry is $3.08 million. The offering was 90.26% smaller than the average of $3.08 million. Of course this should not be seen as negative. Companies get financed for different reasons and needs. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Manus Biosynthesis Also
The Form D signed by Ajikumar Parayil might help Manus Biosynthesis, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.